TY - JOUR
T1 - Preparation and Optimization of Naringin Oral Nanocarrier
T2 - In Vitro Characterization and Antibacterial Activity
AU - Imam, Syed Sarim
AU - Gilani, Sadaf Jamal
AU - Zafar, Ameeduzzafar
AU - Jumah, May Nasser bin
AU - Ali, Raisuddin
AU - Ahmed, Mohammed Muqtader
AU - Alshehri, Sultan
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - Naringin (NG), is a poorly water-soluble flavonoid that has reported to possess a variety of therapeutic efficacies. The present research work is designed to prepare and optimize Naringin hybrid nanoparticles (NG-HNs) using lipid (A), chitosan (B), and D-α-tocopheryl polyethylene glycol succinate (C). The formulations were optimized using a Box–Behnken Design (BBD), and the selection of optimized composition (NG-HNop) was carried out on the basis of low particle size (Y1) and high entrapment efficiency (Y2) using the point prediction method. The selected NG-HNop was further evaluated in order to study permeation, drug release, antimicrobial and antioxidant effect, and cell viability. The optimized nanoparticles (NG-HNop) showed a particle size and entrapment efficiency of 246 ± 8.3 nm and 83.5 ± 2.1%, with a polydispersibility index (PDI) of 0.23 and a Zeta potential of + 18.1 mV, indicating high stability. The optimized NG-HNop exhibited better drug release (89.62 ± 4.54%) and enhanced permeation (3.7 folds). A significant improvement in the antimicrobial activity was achieved against Escherichia coli with respect to Staphylococcus aureus with the hybrid nanoparticles. They also exhibited better activity in the tested cell line. On the basis of the study results, hybrid nanoparticles of Naringin are an alternative oral delivery method for treating cancer cells.
AB - Naringin (NG), is a poorly water-soluble flavonoid that has reported to possess a variety of therapeutic efficacies. The present research work is designed to prepare and optimize Naringin hybrid nanoparticles (NG-HNs) using lipid (A), chitosan (B), and D-α-tocopheryl polyethylene glycol succinate (C). The formulations were optimized using a Box–Behnken Design (BBD), and the selection of optimized composition (NG-HNop) was carried out on the basis of low particle size (Y1) and high entrapment efficiency (Y2) using the point prediction method. The selected NG-HNop was further evaluated in order to study permeation, drug release, antimicrobial and antioxidant effect, and cell viability. The optimized nanoparticles (NG-HNop) showed a particle size and entrapment efficiency of 246 ± 8.3 nm and 83.5 ± 2.1%, with a polydispersibility index (PDI) of 0.23 and a Zeta potential of + 18.1 mV, indicating high stability. The optimized NG-HNop exhibited better drug release (89.62 ± 4.54%) and enhanced permeation (3.7 folds). A significant improvement in the antimicrobial activity was achieved against Escherichia coli with respect to Staphylococcus aureus with the hybrid nanoparticles. They also exhibited better activity in the tested cell line. On the basis of the study results, hybrid nanoparticles of Naringin are an alternative oral delivery method for treating cancer cells.
KW - Naringin
KW - antimicrobial
KW - antioxidant
KW - cell line
KW - hybrid nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85138642539&partnerID=8YFLogxK
U2 - 10.3390/coatings12091230
DO - 10.3390/coatings12091230
M3 - Article
AN - SCOPUS:85138642539
SN - 2079-6412
VL - 12
JO - Coatings
JF - Coatings
IS - 9
M1 - 1230
ER -